|We have completed all the competition deliverables, including Wiki design, Poster, Presentation Video, Project Promotion Video, and Judging Form.
|The Attribution page has been completed.
|We have completed the Description page.
|We used 4 existing basic parts (BBa_E0040; BBa_I719005; BBa_J61104; BBa_B0012) in our project and we modified the 4 parts to fit in our project.
|We have completed Engineering Page to show our success in engineering. Our engineering success can be verified by parts (BBa_K3423000, BBa_K3423001, and BBa_K3423005).
|We held an offline meetup with Team: SZU_China and discussed our projects with each other.
We participated in CCiC and learned a lot from other teams and received a lot of advice.
We delivered our plasmid to Team: Tsinghua to help in their experiments.
|We have organized Human Practices include scientific communication events, Anti-Biofilm Community as so on.
|We have completed the Proposed Implementation Page.
|Integrated Human Practices
|We continuously consult different people from academia and industry, including medicine, chemical biology, environmental engineering in every important step of our project and have completed Integrated Human Practices.
|We have designed a model to help us evaluate the efficiency of certain protein-DNA interaction (PDI) inhibitors in our reporter system and screen effective PDI inhibitors.
|Proof of Concept
|Combining structural biology and chemical genetics screening, together with organic chemistry, we developed a novel inhibitor of the transcription factor Aca1, which assists phages to infect Pseudomonas. Thus, we are able to help the Pseudomonas to defend against phage infection.
|We deeply collaborated with Team: SCUT_China throughout the year on Pseudomonas and we both benefited from each other.
|We have developed and implemented three meaningful interaction activities related to synthetic biology. And we have completed Education Page.
|Excellence in Another Area
|We constructed a novel screening system (E. coli containing two plasmids) using eGFP as a potent signal reporter to screen for small molecule inhibitors targeting transcription factors.